Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18f]CFT

Annals of Neurology

Volumn 47, Issue 6, 2000, Pages 804-808

  Nurmi, E ^a   Ruottinen, H M ^a   Kaasinen, V ^a   Bergman, J ^a   Haaparanta, M ^a   Solin, O ^a   Rinne, J O ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; FLUORINE 18;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HUMAN; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; BRAIN; CARRIER PROTEINS; CAUDATE NUCLEUS; CEREBELLUM; COCAINE; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034041228     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F     Document Type: Article

References (22)

1. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease, studied with PET. Brain 1990;113:1539-1552
2. 18F] fluorodopa/ PET studies of the PD rate of progression. Mov Disord 1998; 13:(Suppl 2): 108 (Abstract)
3. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319
4. Vingerhoets FJG, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764
5. 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988;77: 192-201
6. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298
7. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;43:423-431
8. Innis RB, Seibyl JP, Scanley BE. et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969
9. Brücke T, Asenbaum S, Pozzera A, et al. Dopaminergic nerve cell loss in Parkinson's disease quantified with [I-123]-β-CIT and SPECT correlates with clinical findings. Mov Disord 1994; 9(Suppl 1):120 (Abstract)
10. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103
11. 123I]β-CIT-FP. Parkinsonism and Related Disorders 1997;3:77-81
12. 18F]β-CFT, is reduced in early Parkinson's disease. Synapse 1999;31:119-124
13. 11C]β-CIT in Parkinson's disease. J Nucl Med 1995;36:1263-1267
14. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-1583
15. 123I]β-CIT SPECT. Parkinsonism and Related Disorders 1995;1:47-52
16. 123I]β-CIT striatal uprake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598
17. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140
18. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. Synapse 1996;23:321-327
19. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse 1998;28:244-250
20. Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24:677-683
21. 123I]CIT and SPECT: an imaging biomarker of Parkinson's disease progression. Neurology 1999;50(Suppl 4):329 (Abstract)
22. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726